Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1292325
- By:
- Publication type:
- Article
Works by Ruwei Xing
Results: 10
1
2
MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma.
- Published in:
- Holistic Integrative Oncology, 2024, v. 3, n. 1, p. 1, doi. 10.1007/s44178-024-00094-9
- By:
- Publication type:
- Article
3
Therapeutic perspectives for adult soft tissue sarcoma-updates from the 2022 ASCO annual meeting.
- Published in:
- Cancer Biology & Medicine, 2022, v. 19, n. 10, p. 1496, doi. 10.20892/j.issn.2095-3941.2022.0394
- By:
- Publication type:
- Article
4
The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.
- Published in:
- Cancer Biology & Medicine, 2022, v. 19, n. 6, p. 910, doi. 10.20892/j.issn.2095-3941.2021.0270
- By:
- Publication type:
- Article
5
Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
- Published in:
- Cancer Biology & Medicine, 2020, v. 17, n. 2, p. 501, doi. 10.20892/j.issn.2095-3941.2019.0397
- By:
- Publication type:
- Article
6
A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34877-3
- By:
- Publication type:
- Article
7
Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.
- Published in:
- Experimental & Molecular Medicine EMM, 2019, v. 51, n. 3, p. 1, doi. 10.1038/s12276-019-0221-7
- By:
- Publication type:
- Article
8
Tumoral C2 Regulates the Tumor Microenvironment by Increasing the Ratio of M1/M2 Macrophages and Tertiary Lymphoid Structures to Improve Prognosis in Melanoma.
- Published in:
- Cancers, 2024, v. 16, n. 5, p. 908, doi. 10.3390/cancers16050908
- By:
- Publication type:
- Article
9
Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-41089-1
- By:
- Publication type:
- Article
10
Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas.
- Published in:
- Frontiers in Oncology, 2022, v. 11, p. 1, doi. 10.3389/fonc.2021.778774
- By:
- Publication type:
- Article